Before the Bell
$
152.49
Change
+0.38 +0.25%
Volume
Volume 115
Nov 30, 2023, 4:56 a.m.
Real time quotes
Previous close
$ 152.11
$ 152.11
Change
+0.48 +0.32%
Day low
Day high
$151.07
$152.20

52 week low
52 week high
$144.95
$181.04

Market cap
$365.02B
Average volume
6.44M
P/E ratio
29.03
Rev. per Employee
$624,414
EPS
5.24
Dividend
1.19
Div yield
3.13%
Ex dividend date
11/20/23
MarketWatch News on JNJ
-
Finding Solid Dividends in Emerging Markets
- Lawrence C. Strauss
-
A Golden Age of Vaccines Is Here. What It Means for You.
- Neal Templin
-
Beneath October’s CPI Number: Inflation’s Untold Stories
- Angela Palumbo
-
Pharma's Out of Favor. 5 Drug Stocks That Can Grow.
- Josh Nathan-Kazis
-
Alcon’s stock falls as third-quarter sales miss estimates
- Eleanor Laise
-
Grab these 2 funds with rich 11%-12% yields while you can
- Michael Brush
-
Pharma Stocks Are Bleeding. 2 Look Like Bargains.
- Josh Nathan-Kazis
-
Drug Stocks Keep Tanking on Earnings. Brace for More.
- Josh Nathan-Kazis
-
Sanofi to Spin Out Consumer Health Division
- Josh Nathan-Kazis
-
5 Consumer Staples Stocks to Buy Now
- Lawrence C. Strauss
-
The Bond Selloff Might Be Over. Buy These Stocks to Win.
- Jacob Sonenshine
- Loading more headlines...
Analyst Ratings
-
Analysts Are Overwhelmingly Bullish on Abbott Laboratories
- MarketRealist.com
-
Johnson & Johnson: Analyst Recommendations and Target Price
- MarketRealist.com
-
Wall Street’s Views on BSX’s Acquisition of Cryterion Medical
- MarketRealist.com
Other News on JNJ
-
Barretts Minerals Fights to Keep Bankruptcy Case in Texas
- The Wall Street Journal Interactive Edition
-
The Stocks That AI Mania Left Behind
- The Wall Street Journal Interactive Edition
-
Bayer Stock Falls On Trial Halt, Roundup Verdict
- The Wall Street Journal Interactive Edition
-
Medical Studies Are Too White. Science Aims to Get Better Data.
- The Wall Street Journal Interactive Edition
-
Warren Buffett’s Berkshire Hathaway Sheds Investments in GM, J&J, P&G
- The Wall Street Journal Interactive Edition
-
Bayer Mulls Possible Split of Crops or Consumer Health
- The Wall Street Journal Interactive Edition
-
How Ozempic Maker’s Very Danish Capitalism Fueled Success—and Stumbles
- The Wall Street Journal Interactive Edition
-
Why Drug Companies Don’t Want to Sell Allergy Medicines and Bandages Anymore
- The Wall Street Journal Interactive Edition
-
This $5 Billion Biotech Home Run Took Less Than a Year
- The Wall Street Journal Interactive Edition
-
Johnson & Johnson Considers Ditching Texas Two-Step for Third Talc Bankruptcy
- The Wall Street Journal Interactive Edition
-
Bond Yields Hit Fresh Multiyear Highs After Hot Retail Sales Data
- The Wall Street Journal Interactive Edition
-
Johnson & Johnson’s Latest Talc Lawsuit Victory
- The Wall Street Journal Interactive Edition
-
CIOs Feel Heat From CEOs on Generative AI
- The Wall Street Journal Interactive Edition
-
Change Is Slow on Corporate Boards
- The Wall Street Journal Interactive Edition
-
This Cancer Therapy is Lifesaving, but There Isn’t Enough of It
- The Wall Street Journal Interactive Edition
-
Prison Health Contractor Expands Texas Two-Step Bankruptcy Tactic
- The Wall Street Journal Interactive Edition
-
J&J Revamps Drug Research, Plots Medical Device Deals
- The Wall Street Journal Interactive Edition
-
Big Pharma’s Battle With the Biden Administration Could Have Legs
- The Wall Street Journal Interactive Edition
-
J&J’s $40 Billion Split-Off Sets Stage for Pharma, Medical Tech Expansion
- The Wall Street Journal Interactive Edition
-
Health Care Roundup: Market Talk
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on JNJ
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com